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Abstract. The present study aimed to investigate the 
anti-cancer activity of imidazo[1,2-a]pyridine 5-7 in the A375 
and WM115 melanoma and HeLa cervical cancer cell lines. 
The viability of cancer cells was analyzed by the MTT assay. 
Apoptosis was quantified by flow cytometry following staining 
of the cells with AnnexinV/propidium iodide (PI). The cell 
cycle was evaluated by flow cytometry after staining of cells 
with PI. The three compounds inhibited the proliferation of 
all cells for half maximal inhibitory concentration ranging 
from 9.7 to 44.6 µM following 48-h treatment. In addition, 
all cancer cells were more sensitive to compound 6 compared 
with the other compounds. Treatment with compound 6 
induced G2/M cell cycle arrest and a significant increased 
level of intrinsic apoptosis in all tested cells. Furthermore, 
compound 6 reduced the levels of phospho (p)-protein 
kinase B and p-mechanistic target of rapamycin, and increased 
levels of the cell cycle inhibitors p53 and p21 and of the 
apoptosis-associated proteins BCL2 associated X protein 
and active caspase-9. Silencing p53 in A375 melanoma cells 
reduced compound 6-induced apoptosis, which suggested that 
compound 6 may induce p53-partially mediated apoptosis. 
These results demonstrated that imidazo[1,2-a]pyridines 5-7 
are potential effective compounds in the treatment of mela-
noma and cervical cancers.
Introduction
Cervical cancer and melanoma are aggressive cancers with 
increasing incidence worldwide (1). Whereas cervical cancer 
ranks fourth cancer for both incidence and mortality, malignant 
melanoma is the most serious type of skin cancer and accounts 
for the majority of skin cancer-associated mortalities (1,2). 
Cervical cancer is commonly treated with a combination of 
radiotherapy and platinum-based chemotherapy, which may 
also damage normal cells (3). At present, there is no globally 
accepted standard treatment that offers a significant survival 
benefit for patients with advanced‑stage melanoma (2). Until 
2011, the chemotherapeutic drugs dacarbazine, temozolomide 
and fotemustine were most commonly used for metastatic 
melanoma treatment (4); however, only a low percentage of 
patients who received these compounds exhibited a signifi-
cant response. These treatments have been mostly replaced 
by the immune-checkpoint inhibitors, including cytotoxic 
T-lymphocyte-associated protein-4 (CTLA-4), B-Raf 
proto-oncogene (BRAF) and mitogen-activated protein kinase 
kinase (MEK) inhibitors (5). However, these therapeutic alter-
natives display adverse events, including secondary cutaneous 
squamous cell carcinomas and keratoacanthomas, which 
occur in ~20% of patients treated with BRAF-inhibitor (6). A 
previous study reported that MEK inhibitors have more serious 
adverse effects and a lower efficacy compared with BRAF 
inhibitors (5). The development of novel effective agents for 
the treatment of these cancers is therefore crucial.
Imidazopyridines possess a wide range of biological 
activities. In particular, the imidazo[1,2-a]pyridine moieties 
of imidazopyridine have recently gained significant interest 
as potential anticancer agents due to their potent inhibi-
tory role of cancer cell growth, which is commonly due to 
survival kinases inhibition (7,8). Various drugs containing 
imidazo[1,2-a]pyridine moieties are currently used to 
treat cardiac disorders, insomnia, antianxiety, ulcers 
and HIV infections (9). Although these compounds have 
numerous medicinal applications, none of them have been 
accepted as an anti-cancer drug. However, previous studies 
have reported that imidazo[1,2-a]pyridines have some 
anti-cancer abilities. For example, Goel et al (9) recently 
reported that 3‑{1‑[(4‑fluorophenyl)sulfonyl]‑ 1H-pyrazol- 
3-yl}-2-methylimimoredazo[1,2-a]pyridine may be a 
novel PIK3CA inhibitor with an half maximal inhibitory 
concentration (IC50) of 0.67 µM. Further optimization of 
the substituents resulted in thiazole groups substituted by 
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imidazo[1,2-a]pyridines, which are more potent inhibitor 
of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic 
subunit alpha (PI3KCA) with an IC50 of 0.0028 µM (10). In 
addition, this compound exerts a promising anti-prolifera-
tion effect against melanoma (A375) and cervical (HeLa) 
cancer cells, with IC50 values of 0.14 and 0.21 µM, respec-
tively. notably, 50 mg/kg of this compound significantly 
inhibits HeLa human cervical tumor xenografts growth in 
mice. Additional series of imidazo[1,2-a]pyridine deriva-
tives were designed and synthesized as PI3Kα inhibitors (6). 
One of these compounds, comprising the bioisosteric 
1,2,4-oxadiazole group as a substituent, exhibits potent 
PI3Kα inhibition with an IC50 of 2 nM. In addition, this 
compound inhibits various types of breast cancer cell 
line proliferation with an IC50 of >10 µM. Furthermore, 
Annexin V results demonstrated that it significantly 
increases T47d breast cancer cell apoptosis. At a molecular 
level, these effects are associated with PI3K signaling inhi-
bition. Notably, this compound has some anti-angiogenic 
effects through VEGF expression inhibition. In addition, 
ethyl 6-(5-(phenyl sulfonamide)pyridin-3-yl)imidazo[1,2-a]
pyridine-3-carboxylate was also reported (11). This 
compound has significant anti‑cancer activity in non‑small 
cell lung cancer cells. Cell treatment with this compound 
inhibits the phospho (p)-protein kinase B (PI3K)-protein 
kinase B (Akt)-mechanistic target of rapamycin (mTOR) 
pathway-induced intrinsic apoptosis (11). A recent study 
reported that selenylated imidazo[1,2-a]pyridines inhibits 
breast cancer cell proliferation by inducing dNA damage 
and apoptosis (12). Additional anti-cancer properties of 
imidazo[1,2-a]pyridines, including inhibition of nicotin-
amide phosphoribosyltransferase (13), cyclin-dependent 
kinases (14) and insulin-like growth factor 1 receptor tyro-
sine kinase (8) were also reported.
The present study aimed to investigated the anticancer 
activities of three imidazo[1,2-a]pyridines, the compounds 5-7, 
in melanoma and cervical cancer cells through analyses of the 
Akt/mTOR pathway, the cell cycle and apoptosis.
Materials and methods
Chemicals and reagents. Chemicals and solvents, radioim-
munoprecipitation assay (RIPA) lysis buffer (cat. no. R0278) 
were used without further purification and were supplied by 
Sigma-Aldrich; Merck KGaA (darmstadt, Germany), unless 
otherwise stated. Media and cell culture reagents were from 
Biological Industries (Kibbutz Beit Haemek, Israel). Western 
blotting reagents were obtained from Bio-Rad Laboratories Inc. 
(hercules, CA, UsA). dAPi and primary antibodies against 
poly(AdP-ribose) polymerase 1/2 (PARP1/2; cat. no. sc-7150), 
p53 (cat. no. sc-126), p21 (cat. no. sc-756), BCL2 associated X 
protein (BAX; cat. no. sc-7480), cyclin B (cat. no. sc-sc-53236), 
AKT (cat. no. sc-514032) and tubulin (cat. no. sc-5286) were 
purchased from Santa Cruz Biotechnology, Inc. (dallas, TX, 
UsA). Primary antibodies against B‑cell lymphoma 2 (BCL2; 
cat. no. 2876) and caspase-9 (cat. no. 9502) were provided 
by Cell signaling Technology, inc. (danvers, MA, UsA). 
Horseradish peroxidase-conjugated secondary antibodies 
were provided by Bio-Rad Laboratories, Inc. (Hercules, CA, 
UsA) and electrochemiluminescence reaction (eCL) detection 
system was purchased from Thermo Fisher scientific, inc. 
(Waltham, MA, UsA).
Synthesis of compounds 5‑7. Triethylamine (0.6 g, 0.006 mol) 
diluted in 10 ml dry tetrahydrofuran (THF) was dropwise added 
to a stirring solution of hydrazonoyl chloride 1 (0.005 mol) and 
substituted picolines 2-4 (0.65 g, 0.006 mol) in 25 ml THF 
at room temperature. Stirring was continued overnight, and 
the solvent was evaporated in vacuo. The residual solid was 
washed with water to remove the triethylammonium salt, and 
the crude products were recrystallized from the appropriate 
solvents to obtain the compounds 5-7. The physical data 
of these compounds are available in the original publica-
tion (15). The chemical formulas of the three compounds 
were as follows: 3-[(4-Chlorophenyl)diazenyl]-2,8- dimethy-
limidazo[1,2- a]pyridine (compound 5), 3-[(4-Chlorophenyl)
diazenyl]- 2,7- dimethylimidazo[1,2-a]pyridine (compound 6) 
and 3-[(4-Chlorophenyl)diazenyl]-2,5-dimethylimidazo[1,2- 
a]pyridine (compound 7).
Cell culture and treatments. The human melanoma cell lines 
A375 and WM115 and the cervical cancer cell line HeLa, 
sourced from the department of human Biology, University 
of Cape Town (Cape Town, South Africa), were maintained 
in dulbecco's modified eagle's medium supplemented with 
10% fetal bovine serum and placed at 37˚C in a humidified 
incubator containing 5% CO2. Compounds 5-7 were dissolved 
in dimethyl sulfoxide (dMSO) to obtain 10 mM stock solu-
tions that were stored at room temperature for a maximum 
of 10 days. Control cells were treated with equivalent 
concentrations of dMSO (vehicle).
Small interfering RNA (siRNA). Suppression of p53 expres-
sion was achieved by siRnA that specifically targeted p53 
mRnA. Cells at 70% confluence were transfected with 50 nM 
anti-p53 siRNA (cat. no. sc-756) or a scrambled control RNA 
(cat. no. sc-37007) from Santa Cruz Biotechnology, Inc. 
(dallas, TX, UsA) using Lipofectamine® 2000 (Thermo 
Fisher Scientific, Inc.) according to the manufacturer's 
instructions. The transfection reagent and siRNA complex 
were added drop-wise to the cells and incubated for 30 h at 
37˚C. The subsequent experiments were performed 30 h after 
transfection.
Cytotoxicity assays. Cells were seeded in 96-well plates at 
4-5x103 cells per well and allowed to settle for 48 h. Cells 
were treated with increasing concentrations of compounds 5-7 
(0-100 µM) or vehicle for 48 h. Cytotoxicity was assessed 
using MTT assay (Roche diagnostics GmbH, Mannheim, 
Germany) (16) according to the manufacturer's instructions. 
Briefly, 10 µl MTT solution was added to each well and cells 
were incubated at 37˚C for 4 h. The solubilization buffer 
(100 µl, 10% SdS in 0.01 M hydrochloric acid) was added on 
cells for 16 h at 37˚C. Absorbance was determined at 585 nm 
with a microplate reader, and the mean cell viability was 
calculated as a percentage of the mean vehicle control.
Cell cycle analysis. The effect of compound 6 on the cell cycle 
profile of cancer cells was determined according to a previous 
protocol (17). Briefly, cells were seeded at 3‑4x105 cells per 
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6-cm dish and allowed to settle for 24 h. Log-phase cultures 
were exposed to compounds 5-7 (0 to 100 µM) or vehicle for 
48 h. Cells were trypsinized, washed with PBs and fixed over-
night in 95% ethanol at 4˚C, and subjected to Rnase treatment 
and stained for 30 min at room temperature with propidium 
iodide (PI; 500 µg/ml; Sigma-Aldrich; Merck KGaA). Cellular 
dNA content was determined by flow cytometry with a 
FACsCalibur flow cytometer with a 488 nm Coherent laser 
(Bd Biosciences, Franklin Lakes, nJ, UsA). The CellQuest 
Pro version 5.2.1 software (Bd Biosciences) was used for 
data acquisition and analyses were performed using Modfit 
version 2.0 software (Bd Biosciences).
Detection of apoptosis. Log‑phase cultures (60‑70% conflu-
ence) were treated with compound 6 or vehicle for 48 h. 
Adherent and floating cells were collected and double‑labelled 
with Annexin V-Fluorescein isothiocyanate (FITC) and PI 
(Sigma-Aldrich; Merck KGaA) for 10 min at room tempera-
ture. Annexin V-FITC was used to determine apoptotic 
cells percentage whereas PI stained all dead cells. Cells 
were analyzed by flow cytometry with a 488 nm Coherent 
laser equipped with FACStation running Cellquest software 
(Bd Biosciences).
Nuclear fragmentation. Melanoma and cervical cancer cells 
were treated with compound 6 (10 and 35 µM, respectively) 
for 24 h at 37˚C and stained with dAPi (10 µg/ml) nuclear 
stain for 10 min at room temperature. Cells were observed by 
fluorescence microscopy (Zeiss Gmbh, Jena, Germany).
Western blotting. Cells were harvested with RIPA lysis buffer 
for 30 min on ice. The lysates were collected, and the protein 
concentrations were determined using Bradford's reagent 
(Bio-Rad Laboratories, Inc.), according to the manufacturer's 
instructions and using albumin as a standard. A total of 20 µg 
protein was separated by 8-15% SdS-PAGE, and transferred 
to a Hybond ECL nitrocellulose membrane (GE Healthcare, 
Chicago, iL, UsA) (17). Following blocking for 1 h at room 
temperature with PBS containing 0.05% Tween-20 and 
5% powdered skim milk, membranes were incubated overnight 
with primary antibodies (1:1,000) at 4˚C. After primary anti-
body incubation, membranes were incubated with appropriate 
HRP-conjugated secondary antibodies (1:5,000) for 1 h at room 
temperature. Bands were detected using enhanced chemilu-
minescence detection system (Thermo Fisher scientific, inc., 
Waltham, MA, UsA) (18). Relative expression level of the 
proteins was analyzed by Un‑sCAn‑iT gel 6.1 software by 
silk scientific Corporation (Orem, UT, UsA) and normalized 
to the loading controls.
Statistical analysis. Results are presented as the mean ± standard 
error of the mean (SEM) of the three independent experiments. 
Statistical analysis of data was performed using the two-sample 
t-test in Microsoft Excel 2013 (Microsoft Corporation, 
Redmond, WA, UsA) or a one‑way AnOVA with Tukey's post 
hoc test in Graph Pad Prism (version 5; GraphPad Software, 
inc., La Jolla, CA, UsA). P<0.05 was considered to indicate a 
statistically significant difference.
Results
Imidazo[1,2‑a]pyridines induces cytotoxicity and cell 
cycle arrest. Imidazo[1,2-a]pyridines 5-7 were synthesized 
according to our published method (15). As presented in 
Fig. 1, the reaction of hydrazonoyl chloride 1 with the 
appropriate substituted methyl-2-aminopicolines 2-4 in 
the presence of triethylamine as a base at 0˚C gave the 
compounds 5-7 (Fig. 1).
The cytotoxic effects of compounds 5-7 on melanoma and 
cervical cancer cell lines were investigated. A375, WM115 
and HeLa cells were treated with increasing concentration of 
compounds 5-7 (0 to 100 µM) for 48 h prior to assessing cell 
viability with MTT assay. The results demonstrated that all 
compounds inhibited cell proliferation of the three cell lines 
with different IC50 ranging from 9.7 to 44.6 µM (Fig. 2A). 
Notably, compound 6 was the most potent compound to 
induce melanoma and cervical cancer cell toxicity. In addition, 
compound 6 was more toxic to melanoma cells than cervical 
cancer cells. The effect of compound 6 on cell cycle profile was 
then explored. To do so, melanoma and cervical cancer cells 
were treated with 10 and 35.0 µM compound 6, respectively, for 
48 h prior to analyzing cell cycle. The results in Fig. 2B and C 
demonstrated that compound 6 induced a significant G2/M cell 
cycle arrest in all cell lines, which was mainly at the expense 
of G1 phase cell populations. In addition, A375 cell treatment 
with compound 6 caused an increase in the cell population 
Figure 1. Schematic representation of the imidazo[1,2-a]pyridines 5-7 compounds synthesis and structures (15). Et3N, triethylamine; THF, tetrahydrofuran.
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in the G2/M phase from 2.58±3.1% (control) to 24.59±2.4%. 
Similarly, WM115 cell treatment with compound 6 increased 
cell population in the G2/M from 12.49±2.6% (control) to 
23.93±4.2%. In cervical cancer cells, compound 6 treatment 
increased the G2/M phase cell population from 13.23±3.5% 
(control) to 24.17±5.6%. notably, whereas no significant effects 
of compound 6 were observed on the S phase of melanoma 
cells, heLa cells treated with compound 6 exhibited a signifi-
cant increase in the S phase cell population which raised from 
9.24±2.3% (control) to 23.37±4.8%. These results suggested 
that compounds (5-7), particularly compound 6, may inhibit 
cancer cells proliferation and induce G2/M cell cycle arrest in 
cancer cells.
Compound 6 induces intrinsic apoptosis. To determine 
whether compound 6 induced apoptotic cell death, mela-
noma and cervical cancer cells were treated with 10 and 
35.0 µM compound 6, respectively, for 48 h and stained with 
Pi and Annexin V‑FiTC. The results from flow cytometry 
demonstrated that compound 6 significantly increased 
apoptosis in all cancer cell lines (Fig. 3A). In addition, the 
levels of apoptotic melanoma cells were higher than the 
levels of apoptotic HeLa cells following compound 6 treat-
ment. A375 cells treated with 10 µM of compound 6 for 
48 h increased significantly from 4.58±2.34% (control) to 
27.38±3.4%. Similar results were obtained for WM115 cells 
that exhibited an increase in apoptosis from 3.48±1.49% 
(control) to 22.49±3.23% following 48-h treatment with 
10 µM compound 6. However, the level of apoptosis induced 
by 35 µM compound 6 was only 16.38±3.23% in HeLa cells. 
In addition, following nuclear staining and fluorescence 
microscopy analysis, cancer cells treated with compound 6 
exhibited fragmented chromatin, which was characteristic of 
apoptotic cells (Fig. 3B). To further confirm that compound 6 
induced apoptosis at a molecular level, and to investigate 
the mechanisms underlying compound 6-induced cell death, 
western blotting of key apoptotic proteins, including cleaved 
PARP, BAX, BCL2 and caspase-9 were performed (Fig. 3C). 
The results demonstrated that PARP cleavage was increased 
in all cancer cell lines following 24 and 48 h of treatment 
with compound 6. Furthermore, the markers of intrinsic 
apoptosis, including BAX cleaved caspase-9, were increased 
in the three cancer cell lines following 48 h of treatment with 
compound 6. In addition, the level of the anti-apoptotic protein 
BCL2 decreased in all treated cells. These results indicated 
that compound 6 induced intrinsic apoptotic pathways in 
melanoma and cervical cancer cell lines.
Compound 6 inhibits AKT/mTOR pathway. Previous studies 
have reported the ability of different imidazo[1,2-a]pyri-
dines to inhibit AKT/mTOR pathway in cancer cells (12,13). 
These studies demonstrated that these compounds bind to 
the ATP-binding site of PI3K with a high affinity, which 
induces the PI3K/AKT/mTOR pathway inhibition. To inves-
tigate whether compound 6 exerts its effect through the 
same mechanism, western blotting of key proteins from this 
pathway, including p‑AKT (using the specific antibody for 
phosphorylated Ser 473 of Akt1), AKT and p-mTOR were 
performed. The results demonstrated that both p-AKT and 
p-mTOR levels were reduced in all cancer cells following 48-h 
treatment with compound 6 (Fig. 4A). These results indicated 
that compound 6 inhibited AKT, which may regulate other 
important proteins, including as p53.
Figure 2. Compounds 5-7 inhibit cancer cell proliferation. (A) IC50 values 
for the treatment of A375, WM115 and HeLa cell lines with compound 6 for 
48 h. Cell survival rate was measured by MTT assay and IC50 values were 
calculated from sigmoidal plots with GraphPad Prism version 5. Results 
represented the means ± standard error of the mean of at least three experi-
ments performed in quadruplicate. (B) A375 and WM115 cells were treated 
with vehicle or compound 6 (10 µM), and HeLa cells were treated with 
vehicle or compound 6 (35 µM) for 48 h. Cell cycle profile was determined 
by cell staining with propidium iodide and dNA content was assessed by 
flow cytometry. (C) Proportion of cells in the G2/M phase was expressed 
as a percentage of the total number of cells analyzed and represented as the 
means ± standard error of the mean of at least three experiments. *P<0.01, 
one way analysis of variance with Tukey post-test comparing treated samples 
to the relevant untreated control. IC50, half maximal inhibitory concentration.
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p53 partially mediates compound 6 cytotoxicity. A previous 
study revealed that AKT facilitates p53 degradation by 
increasing MdM2 proto-oncogene expression (19). The 
effect of compound 6 on p53 response was therefore investi-
gated. To do so, western blotting of p53 and its downstream 
target p21was performed. As presented in Fig. 4A, p53 and 
p21 protein levels were increased in all cancer cells following 
treatment with compound 6. In addition, treatment with 
compound 6 reduced cyclin B level in all cancer cells which 
supports the G2/M cell cycle arrest detected as shown in 
Fig. 2B and C. The potential roles of p53-mediated signaling 
in compound 6-induced cell death were investigated 
by inhibiting p53 expression via si-RNA transfection. 
A375 cells transfected with sip53 presented attenuated 
p21 expressions in control and compound 6-treated cells 
(Fig. 4B). This was further evidenced by the decreased 
level of cleaved PARP observed following compound 6 
treatment in A375 sip53 cells (Fig. 4B). These observations 
were reinforced by Annexin V assay, which demonstrated 
that compound 6 treatment induced a moderate increase in 
apoptosis (15.65±3.23%) in A375 sip53 cells, compared with 
un-transfected cells (34.23±3.45%) (Fig. 4C). These obser-
vations suggested that compound 6 may induce apoptosis 
partly through p53 regulation.
Figure 3. Compound 6 activates intrinsic apoptosis. (A) Flow cytometry analyses of Annexin V‑fluorescein isothiocyanate/propidium iodide staining presented 
the apoptosis induction in melanoma and cervical cells treated with compound 6 at 10 and 35 µM, respectively, for 48 h. The graph represented the percentage 
of cells undergoing apoptosis (early and late) and the results are presented as the mean of three independent experiments ± standard error of the mean. *P<0.05. 
(B) Fluorescence microscopy demonstrated that cancer cells treated as in (A) and stained with dAPI displayed fragmented chromatin characteristic of 
apoptotic cells. (C) Western blotting of proteins from cancer cells treated as in (A) presented BAX, BCL2, caspase-9 and cleaved PARP levels. BCL2, B-cell 
lymphoma 2; BAX, BCL2 associated X protein; FiTC, fluorescein isothiocyanate, PARP, poly(AdP‑ribose) polymerase.
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Figure 4. Compound 6 inhibits AKT/mTOR pathway and induces p53 dependent apoptosis. (A) Melanoma cells and HeLa cells were treated with vehicle or 
compound 6 at 10 and 35 µM, respectively, for 48 h. p-AKT, AKT, p-mTOR, p53, p21, cyclin B and tubulin proteins were analyzed by western blotting. (B) A375 
cells were transfected with sip53 and treated with compound 6 (10 µM) for 48 h. Protein extracts were harvested and p53, p21 and PARP were analyzed by 
western blotting. (C) Annexin V/propidium iodide double staining exhibited a percentage of cell death induced by compound 6 after sip53 transfection lower 
than in the un-transfected group (B). *P<0.05. AKT, protein kinase B; c, control; mTOR, mechanistic target of rapamycin; p, phospho; si, small interfering.
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Discussion
The PI3K-AKT signaling pathway is one of the most inves-
tigated cascades in cancer cells. Increasing evidence has 
confirmed the crucial role of the PI3K-AKT pathway in 
cancer initiation and progression (18). The phosphatase 
and tensin homolog (PTEN) tumor suppressor is the most 
common regulator of this pathway, and tumors exhibiting 
PTEN loss usually have a high p-AKT level (20). In vitro 
and in vivo investigations have demonstrated that tumors 
with mutant proto-oncogene B-Raf (BRAF) also present 
high p-AKT levels, which may contribute to the development 
of BRAF-inhibitor resistance (19,20). Similarly, PI3K-AKT 
pathway is commonly dysregulated in cervical cancer, which 
indicates that it may be a potential therapeutic target in the 
treatment of melanoma and cervical cancer (21). Numerous 
PI3K inhibitors have been developed and recently evaluated 
in clinical trials. These comprise PI3K specific inhibitors 
and dual targets inhibitors, including PI3K-mTOR and AKT 
inhibitors (11,22). Subsequently, some imidazo[1,2-a]pyridine 
compounds were developed and tested for their PI3K-AKT 
pathway inhibiting ability (23-25). Our group has therefore 
designed and synthesized novel imidazo[1,2-a]pyridines 
(compounds 5-7) (15). The current study, aimed to investigate 
the exact anticancer effect of these compounds in melanoma 
and cervical cancer cells. Notably, compound 6 exhibited the 
most potent cytotoxic effect in both types of cancer cell. The 
anticancer effect of compound 6 and its mechanism of action 
in melanoma and cervical cancer cell lines were therefore 
deeper examined. The results from this study suggested that 
compound 6 may be considered as a promising novel chemo-
therapeutic drug for melanoma and cervical cancers treatment.
Compound 6 exhibited potent cytotoxicity in A375 and 
WM115 cell lines with low IC50 values (<12 µM), which was 
of crucial importance, considering that metastatic melanoma 
cells seem to be resistant to chemotherapy. For example, the 
dose of dacarbazine, which is the common current treatment 
of metastatic melanoma, necessary to inhibit melanoma cell 
proliferation is ~25 µM (18). However, some imidazo[1,2- 
a]pyridines presented similar or more potent cytotoxicity 
against melanoma cancer cells (23,24). A novel series of 
imidazo[1,2-a]pyridine compounds inhibit A375 human 
melanoma cell line proliferation with a low IC50 <1 µM (23). 
A recent study that screened the cytotoxic effects of novel 
pyrido-imidazodiazepinones reported that seven of these 
compounds significantly inhibit melanoma cell growth at 
1 µM (24).
In the present study, cancer cell treatment with compound 6 
induced a decrease in p-AKT level. This effect was observed 
after 24 h in HeLa cells, and was even more important 
following 48-h treatment with compound 6 in melanoma cells. 
Notably, AKT inhibition was mirrored with the inhibition of its 
downstream target mTOR. Previous studies have reported that 
AKT and target m-TOR inhibitions increase p21 expression 
and activate checkpoint kinase 2, which results in G2/M cell 
cycle arrest (26-28). Furthermore, these studies showed that 
the blockage of cell cycle arrest at the G2/M phase is associated 
with a decrease in the cell cycle regulatory protein cyclin B 
level. Similarly, the results from the present study demon-
strated that compound 6 induced a decrease in cyclin B1 level. 
Notably, compound 6 increased p53 and p21 levels, which 
could explain the G2/M cell cycle arrest observed.
The PI3K/AKT/mTOR pathway is involved in cell survival, 
and its inhibition results in high p53 and BAX apoptotic 
proteins levels (18). Active BAX disrupts the mitochondrial 
membrane integrity and induces the cytochrome c release from 
mitochondria into the cytosol. Cytoplasmic cytochrome c and 
active caspase-9 are then involved in the apoptosome forma-
tion and caspase-3 activation (29). However, cytochrome c 
release does not happen when the anti-apoptotic protein BCL2 
is present. The present study demonstrated that compound 6 
stimulated intrinsic apoptosis by increasing BAX and active 
caspase-9 levels, and decreasing BCL2 level. The results 
suggested that the G2/M cell cycle arrest and intrinsic apop-
tosis induced by compound 6 may be mediated by AKT/mTOR 
inhibition. notably, p53 silencing significantly decreased the 
compound 6-induced apoptosis, which suggested that p53 may 
serve an important role in compound 6-induced cell apoptosis. 
Numerous imidazopyridine derivatives are currently used 
in the clinic for the treatment of other diseases, including 
alpidem (anxiolytic) and zolpidem (hypnotic), which exhibit 
low toxicity levels (30). This could indicate that the compounds 
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